| scholarly article | Q13442814 |
| P356 | DOI | 10.1126/SCITRANSLMED.AAL5253 |
| P698 | PubMed publication ID | 28615361 |
| P50 | author | Rebecca Ellston | Q38804485 |
| Anna D Staniszewska | Q52430540 | ||
| Alexey S Revenko | Q91736030 | ||
| Sarah J Ross | Q95966782 | ||
| Sanjay K Pandey | Q95966784 | ||
| Linda K Buckett | Q95966785 | ||
| Stephanie K Klein | Q95966786 | ||
| Paul D Lyne | Q95966787 | ||
| Robert Macleod | Q95966790 | ||
| P2093 | author name string | Michael Zinda | |
| Kevin Hudson | |||
| Brett P Monia | |||
| Claire Rooney | |||
| David C Blakey | |||
| Mitchell Revill | |||
| Nicky Whalley | |||
| Lyndsey L Hanson | |||
| P433 | issue | 394 | |
| P407 | language of work or name | English | Q1860 |
| P577 | publication date | 2017-06-01 | |
| P1433 | published in | Science Translational Medicine | Q1573955 |
| P1476 | title | Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS. | |
| P478 | volume | 9 |
| Q59791008 | Aberrant RNA Splicing in Cancer and Drug Resistance |
| Q64970925 | Antisense STAT3 inhibitor decreases viability of myelodysplastic and leukemic stem cells. |
| Q48010762 | Cancer: RNA-based approaches target KRAS. |
| Q64099030 | Delivery of GalNAc-Conjugated Splice-Switching ASOs to Non-hepatic Cells through Ectopic Expression of Asialoglycoprotein Receptor |
| Q93015891 | Development and Clinical Trials of Nucleic Acid Medicines for Pancreatic Cancer Treatment |
| Q64100452 | Differential uptake, kinetics and mechanisms of intracellular trafficking of next-generation antisense oligonucleotides across human cancer cell lines |
| Q57462015 | Epigenetic Reprogramming with Antisense Oligonucleotides Enhances the Effectiveness of Androgen Receptor Inhibition in Castration-Resistant Prostate Cancer |
| Q64982130 | Genetic characterisation of molecular targets in carcinoma of unknown primary. |
| Q94533157 | Grifolin, neogrifolin and confluentin from the terricolous polypore Albatrellus flettii suppress KRAS expression in human colon cancer cells |
| Q48531718 | Impact of a five-dimensional framework on R&D productivity at AstraZeneca |
| Q98224914 | Innovative Therapeutic and Delivery Approaches Using Nanotechnology to Correct Splicing Defects Underlying Disease |
| Q55263196 | KRAS mutant allele-specific expression knockdown in pancreatic cancer model with systemically delivered bi-shRNA KRAS lipoplex. |
| Q92733424 | KRAS-specific inhibition using a DARPin binding to a site in the allosteric lobe |
| Q92128564 | MEK nuclear localization promotes YAP stability via sequestering β-TrCP in KRAS mutant cancer cells |
| Q90706520 | New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness |
| Q96302844 | RAS-targeted therapies: is the undruggable drugged? |
| Q56888903 | RNAi-Mediated β-Catenin Inhibition Promotes T Cell Infiltration and Antitumor Activity in Combination with Immune Checkpoint Blockade |
| Q90471584 | Rac1 activates non-oxidative pentose phosphate pathway to induce chemoresistance of breast cancer |
| Q48246978 | Recent advances in the biology and therapy of medullary thyroid carcinoma. |
| Q90429889 | Role of Alternative Splicing in Prostate Cancer Aggressiveness and Drug Resistance in African Americans |
| Q90702089 | Targeted Delivery of Stk25 Antisense Oligonucleotides to Hepatocytes Protects Mice Against Nonalcoholic Fatty Liver Disease |
| Q54962055 | Targeting KRAS in metastatic colorectal cancer: current strategies and emerging opportunities. |
| Q93105571 | Targeting castration-resistant prostate cancer with androgen receptor antisense oligonucleotide therapy |
| Q49519966 | Therapeutic Applications of Targeted Alternative Splicing to Cancer Treatment |
| Q52677752 | Therapeutic oligonucleotides in cardiovascular and metabolic diseases: insights for the internist. |
| Q94564366 | Transcription and Translation Inhibitors in Cancer Treatment |
Search more.